The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumMost Popular - Synageva (NASDAQ:GEVA) announced its third stock offering in twelve months on Thursday, which after a pricing update, should raise approximately $90M for pipeline development, particularly … Continue Reading
Read nowLong Ideas - Endo Health Solutions (NASDAQ:ENDP) re-established financial guidance Thursday night, re-affirming 2012’s prior outlook and, as expected, guiding expectations lower for revenue and EPS in 2013. This … Continue Reading
Read now- Biogen Idec (NASDAQ:BIIB) announced on Thursday that its late-stage amyotrophic lateral sclerosis (ALS) treatment, dexpramipexole, failed to meet its primary endpoint in a Phase III trial, causing … Continue Reading
Read nowMost Popular - Keryx Biopharmaceuticals (KERX) issued a press release on Thursday morning related to the Medicare bundle for oral-only phosphate binders, which would positively impact the company’s lead candidate … Continue Reading
Read nowLong Ideas - AbbVie (NYSE:ABBV), the R&D-focused spinoff of Abbot Laboratories (NYSE:ABT), began its first day of trading on the NYSE on Wednesday, and we expect shares of … Continue Reading
Read now- Navidea Biopharmaceuticals updated its prospectus on Monday afternoon to include 12.5M common shares owned by Platinum-Montaur Life Sciences, which are now available for resale on the open … Continue Reading
Read nowLong Ideas - Shares of BioMarin Pharmaceuticals (NASDAQ:BMRN) have risen roughly 40% in 2012, driven by solid Phase III data for BMRN’s lead investigational product GALNS, a treatment … Continue Reading
Read now
